Mapped protein structure of Hepatitis C could lead to vaccine
Scripps scientists have mapped the protein structure of the Hepatitis C virus, paving the way for an effective vaccine.
List view / Grid view
Scripps scientists have mapped the protein structure of the Hepatitis C virus, paving the way for an effective vaccine.
Researchers from the University of Illinois at Urbana-Champaign found the evolutionary potential of influenza A virus haemagglutinin is extremely restricted by epistatic interactions with neuraminidase.
Texas Biomed and The Access to Advanced Health Institute have been granted $3.5 million to initiate tuberculosis vaccine research, which includes using genetically diverse animal models.
A Boston University researcher has been granted funding for the development pre-clinical models to test potential Nipah virus vaccines.
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
The best protection from COVID-19 will come from intranasally-delivered vaccines, due to the effectiveness of mucosal IgA antibodies, say researchers from the University at Buffalo.
Researchers in the US have developed a potential HIV vaccine approach that aims to prompt the creation of broadly neutralising antibodies via mRNA.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
References for ‘Advancing vaccines with extracellular vesicles’, in Drug Target Review Issue 3 2022.
Scientists have discovered antibodies that are effective against many different COVID-19 variants.
Vaccinating mice with this universal flu candidate induced broad neuraminidase inhibition, M2 ectodomain specific antibodies and T cell immune responses.
Researchers have developed a safe and versatile platform to increase the thermal stability of vaccines and improve their transportability.
Researchers have designed a COVID-19 vaccine to be less sensitive to mutations and equipped for future strains.